Horizon Pharma (HZNP) Tops Q2 EPS by 31c, Raises Guidance

Horizon Pharma (NASDAQ: HZNP) reported Q2 EPS of $0.41, $0.31 better than the analyst estimate of $0.10. Revenue for the quarter came in at $289.5 million versus the consensus estimate of $237.1 million.

GUIDANCE:

Horizon Pharma sees FY2017 revenue of $1.01-1.05 million, versus the consensus of $991.3 million.

• increased its full-year 2017 adjusted EBITDA guidance to $340 million to $375 million from $315 million to $350 mill

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance
• FS Bancorp (FSBW) Tops Q1 EPS by 8c